Back

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: post- ACS patients with elevated atherogenic lipid levels

27 August 2018 (18:25 - 18:35)
Organised by:
Congress Presentation Part of: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data Lipids Open Access ESC Congress 2018

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

6 More presentations in this session

Presentation thumbnail
Welcome and introduction - Highlights from the latest ODYSSEY OUTCOMES data
Professor A. Zeiher (Frankfurt, DE)
Slides Video
Presentation thumbnail
Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes
Professor K. Ray (London, GB)
Slides Video
Presentation thumbnail
Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data
Professor C. Cannon (Boston, US)
Slides Video
Presentation thumbnail
Clinical implications for post-ACS patients
Doctor S. Goodman (Toronto, CA)
Slides Video
Presentation thumbnail
Roundtable: learnings in practice
Professor P. Steg (Paris, FR) Professor A. Zeiher (Frankfurt, DE)
Slides Video

Access the full session

Session thumbnail
Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

The Event

Event poster

ESC Congress 2018

27 August 2018 18:25 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
State-of-the-art lecture on how to keep your arteries young by tackling dyslipidaemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources